Bayforest Capital’s Vaxcyte PCVX Stock Holding History

Bayforest Capital’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	3,706 +3,359	+968%	+$182K	0.2%	152
2026 Q1	$20.2K	Buy	+347	New	+$18.8K	0.02%	727

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bayforest Capital's PCVX Position: Q2 2026 in Review

Bayforest Capital increased its Vaxcyte (PCVX) stake by 968% in Q2 2026, buying an estimated $182K and bringing the position to 3,706 shares worth $215K. The position accounts for 0.2% of the portfolio, ranked #152.

Bayforest Capital first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Bayforest Capital held 3,706 shares of Vaxcyte worth $215K as of Q2 2026.
Bayforest Capital bought 3,359 Vaxcyte shares in Q2 2026, an estimated $182K.
Vaxcyte made up 0.2% of Bayforest Capital's portfolio in Q2 2026, its #152 holding.
Bayforest Capital first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.